In the context of BRAF-mutant melanoma, the persistent activation of the MAPK signaling pathway not only augments cellular proliferation but also disrupts cell death signaling by upregulating the anti-apoptotic protein Mcl-1, ultimately resulting in resistance to BRAF inhibitors [62]. This evidence concerns the gene MCL1 and melanoma.